Chlamydia Antibody Panel, IgM by IFA
Ordering Recommendation

A combined IgG and IgM antibody panel is available (refer to Chlamydia Antibody Panel, IgG & IgM by IFA (0065100)). Differentiate between Chlamydophila species (C. psittaci, C. pneumoniae). Differentiate early IgM response to infection from persistent low-level titer. Because of cross-reactivity, a C. pneumoniae-specific reaction will exhibit titers two-fold or greater than C. trachomatis or C. psittaci serology. Limited value in the diagnosis of most oculogenital (eg, eyes, genitalia) chlamydial infections.

Semi-Quantitative Indirect Fluorescent Antibody
1-4 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Plain red or serum separator tube. 
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as acute or convalescent. 
Storage/Transport Temperature
Unacceptable Conditions
Contaminated, hemolyzed, or hyperlipemic sera. 
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles) 
Reference Interval
< 1:20 C. trachomatis IgM.
< 1:20 C. pneumoniae IgM.
< 1:20 C. psittaci IgM.
Interpretive Data
The Chlamydia antibody test contains both species- and genus-specific antigens, and serological cross-reactions may be seen in both acute and convalescent samples (less than 1:128). A C. pneumoniae-specific reaction will exhibit titers twofold or greater than titers observed with C. trachomatis or C. psittaci serology. Ideally, acute and convalescent samples should be tested simultaneously at the same facility. If the sample submitted was collected during the acute-phase of illness, submit a marked convalescent sample within 25 days for paired testing. Seroconversion, a fourfold or greater rise in antibody titer between acute and convalescent sera, is considered strong evidence of recent infection.

The Chlamydia microimmunofluorescent assay utilizes C. psittaci, C. pneumoniae, and nine serotypes of C. trachomatis. It does not include the LGV strains of C. trachomatis.

Compliance Statement A: For laboratory developed tests using a manufacturer labeled ASR as the reagent providing the specificity of the assay. Analyte Specific Reagent. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, the FDA has determined that such clearance or approval is not necessary.

Hotline History
Component Test Code*Component Chart NameLOINC
0065101C. pneumoniae IgM Titer6914-6
0065102C. trachomatis IgM Titer6920-3
0065103C. psittaci IgM Titer6917-9
0065131Chlamydia IgM Panel Interpretation59464-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Chlamydia IgM Ab
  • CT IgM Ab